MYC and small cell lung carcinoma: Their work revealed that MYC, a key oncogenic driver of SCLC, is not well tolerated in alveolar type II (AT2) cells—the presumed cell-of-origin of LUAD—unless these cells undergo a reprogramming process into a basal-like intermediate state.